Ocuphire Pharma Inc
NASDAQ:OCUP
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
This alert will be permanently deleted.
Ocuphire Pharma Inc
Research & Development
Ocuphire Pharma Inc
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Ocuphire Pharma Inc
NASDAQ:OCUP
|
Research & Development
-$18.2m
|
CAGR 3-Years
-11%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
-14%
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Research & Development
-$14.7B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-5%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Research & Development
-$9.7B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
-7%
|
|
|
Pfizer Inc
NYSE:PFE
|
Research & Development
-$10.1B
|
CAGR 3-Years
6%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-2%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Research & Development
-$15.5B
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
-8%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Research & Development
-$12.6B
|
CAGR 3-Years
-21%
|
CAGR 5-Years
-17%
|
CAGR 10-Years
-11%
|
|
Ocuphire Pharma Inc
Glance View
Ocuphire Pharma, Inc. engages in the research and development of ophthalmic biopharmaceutical products. The company is headquartered in Farmington Hills, Michigan and currently employs 8 full-time employees. The company went IPO on 2004-11-30. Its products include Nyxol Eye Drops and APX3330. The Nyxol Eye Drops is a once-daily preservative-free eye drop formulation of phentolamine mesylate designed to reduce pupil diameter and improve visual acuity. Nyxol is being developed for several indications, including night vision disturbances, reversal of pharmacologically induced mydriasis and presbyopia. The APX3330, is a twice-a-day oral tablet, designed to inhibit angiogenesis and inflammation pathways relevant to retinal and choroidal vascular diseases. Its pre-clinical products are APX2009 and APX2014. APX3330 is in Phase II trial for the treatment of patients with diabetic retinopathy (DR), including moderately severe non-proliferative DR and mild proliferative DR, as well as patients with diabetic macular edema (DME) without loss of central vision.
See Also
What is Ocuphire Pharma Inc's Research & Development?
Research & Development
-18.2m
USD
Based on the financial report for Jun 30, 2024, Ocuphire Pharma Inc's Research & Development amounts to -18.2m USD.
What is Ocuphire Pharma Inc's Research & Development growth rate?
Research & Development CAGR 10Y
-14%
Over the last year, the Research & Development growth was -8%. The average annual Research & Development growth rates for Ocuphire Pharma Inc have been -11% over the past three years , -14% over the past five years , and -14% over the past ten years .
